ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR
· Real-Time Price · USD
2.18
0.15 (7.39%)
At close: Jun 25, 2025, 3:11 PM
ProQR Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Milestone payments Revenue | 5.1M | 6M | 56.25M | 252K |
| Milestone payments Revenue Growth | -15.01% | -89.34% | +22223.02% | n/a |
| Up-front payments Revenue | 15.58M | n/a | n/a | n/a |
| Up-front payments Revenue Growth | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.23M | 3.91M | 3.28M | 3.01M | 2.78M | 3.92M | 3.31M | 4.14M | 4.03M | 2.97M | 5.36M | 5.41M | 4.91M | 5.32M | 4.59M | 4.12M | 3.34M | 3.51M | 2.81M | 3.45M | 3.92M | 3.92M | 2.9M | 2.88M | 3.19M | 4.64M | 2.58M | 2.65M | 2.67M | 2.89M | 2.75M | 2.89M | 2.3M | 2.26M | 2M | 2.62M | 2.6M | 2M | 1.46M | 1.78M | 1.6M |
| Selling, General, and Administrative Revenue Growth | -17.35% | +19.19% | +8.96% | +8.49% | -29.13% | +18.21% | -20.02% | +2.96% | +35.46% | -44.54% | -0.98% | +10.27% | -7.67% | +15.79% | +11.38% | +23.45% | -4.93% | +25.03% | -18.49% | -12.05% | +0.03% | +34.93% | +0.94% | -9.87% | -31.23% | +79.91% | -2.64% | -0.86% | -7.58% | +5.01% | -4.81% | +25.52% | +1.95% | +12.94% | -23.48% | +0.50% | +30.17% | +37.11% | -17.95% | +10.85% | n/a |
| Research and Development Revenue | 12.32M | 10.61M | 9.41M | 7.05M | 9.34M | 7.53M | 5.45M | 5.91M | 6.06M | 10.7M | 15.35M | 11.45M | 13.37M | 12.46M | 11.12M | 9.73M | 8.9M | 8.42M | 8.3M | 8.59M | 12.82M | 13.93M | 11.07M | 9.52M | 11.96M | 9.54M | 6.3M | 5.99M | 7.68M | 8.35M | 7.23M | 7.55M | 8.03M | 8.1M | 8.32M | 8.61M | 6.9M | 6.49M | 6M | 5.43M | 5.48M |
| Research and Development Revenue Growth | +16.13% | +12.72% | +33.57% | -24.52% | +23.93% | +38.35% | -7.84% | -2.49% | -43.36% | -30.31% | +34.09% | -14.35% | +7.31% | +11.97% | +14.27% | +9.32% | +5.77% | +1.38% | -3.30% | -33.04% | -7.94% | +25.80% | +16.29% | -20.40% | +25.37% | +51.53% | +5.13% | -22.06% | -7.91% | +15.49% | -4.32% | -5.95% | -0.86% | -2.63% | -3.33% | +24.76% | +6.22% | +8.23% | +10.56% | -0.97% | n/a |